Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.
作者信息
El Messaoudi Selma, Guedj Jérémie
机构信息
Université Paris Cité, IAME, INSERM, F-75018 Paris, France.
出版信息
JHEP Rep. 2024 Nov 16;7(3):101277. doi: 10.1016/j.jhepr.2024.101277. eCollection 2025 Mar.
Abstract
摘要
相似文献
1
Reply to: Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.
JHEP Rep. 2024 Nov 16;7(3):101277. doi: 10.1016/j.jhepr.2024.101277. eCollection 2025 Mar.
2
Bulevirtide and emerging drugs for the treatment of hepatitis D.
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1245-1253. doi: 10.1080/14712598.2023.2273260. Epub 2023 Dec 28.
3
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.
Lancet Infect Dis. 2023 Jan;23(1):117-129. doi: 10.1016/S1473-3099(22)00318-8. Epub 2022 Sep 13.
4
Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.
JHEP Rep. 2024 Sep 6;7(2):101211. doi: 10.1016/j.jhepr.2024.101211. eCollection 2025 Feb.
5
Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D.
Gastroenterol Hepatol. 2025 Mar;48(3):502241. doi: 10.1016/j.gastrohep.2024.502241. Epub 2024 Sep 7.
6
Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation.
J Hepatol. 2022 May;76(5):1229-1231. doi: 10.1016/j.jhep.2021.12.030. Epub 2022 Jan 5.
7
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
J Hepatol. 2024 Oct;81(4):621-629. doi: 10.1016/j.jhep.2024.05.001. Epub 2024 May 9.
8
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.
JHEP Rep. 2024 Mar 24;6(8):101070. doi: 10.1016/j.jhepr.2024.101070. eCollection 2024 Aug.
9
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr.
10
Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
N Engl J Med. 2024 Jul 11;391(2):133-143. doi: 10.1056/NEJMoa2314134. Epub 2024 Jun 6.
本文引用的文献
1
Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy.
JHEP Rep. 2024 Sep 6;7(2):101211. doi: 10.1016/j.jhepr.2024.101211. eCollection 2025 Feb.
2
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.
JHEP Rep. 2024 Mar 24;6(8):101070. doi: 10.1016/j.jhepr.2024.101070. eCollection 2024 Aug.
3
A Semi-mechanistic Model to Characterize the Long-Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon.
Clin Pharmacol Ther. 2023 Feb;113(2):390-400. doi: 10.1002/cpt.2798. Epub 2023 Jan 11.
4
Understanding silibinin's modes of action against HCV using viral kinetic modeling.
J Hepatol. 2012 May;56(5):1019-1024. doi: 10.1016/j.jhep.2011.12.012. Epub 2012 Jan 13.
5
Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.
Biometrics. 2011 Mar;67(1):250-9. doi: 10.1111/j.1541-0420.2010.01422.x.
Zotero 插件